United States: Nitrosamine Impurities FDA Guidance - Duane Morris LLP

Mondaq

11 Aug 2023 0 shares 1 views

United States: Nitrosamine Impurities FDA Guidance - Duane Morris LLP

Mondaq

Published 11 Aug 2023

On August 4, 2023, the FDA issued a new Guidance to the pharmaceutical industry relating to large molecule drugs left unaddressed in its earlier nitrosamine Guidance publications.

Full Article

United States: FDA Issues Second Warning Letter Of 2023 Over Potentially Misleading Efficacy Claims Regarding Inhaler - Duane Morris LLP

Mondaq 31 Aug 2023

On August 15, 2023, the U.S. Food and Drug Administration (FDA) published a warning letter to AstraZeneca Pharmaceuticals LP,..

United States: Can A Human Behind AI Be Creative? - Duane Morris LLP
Mondaq 31 Aug 2023
United States: FDA Issues Draft Guidance On Pre-market Submissions For Patient-Matched Guides To Orthopedic Implants - Duane Morris LLP
Mondaq 18 Aug 2023
United States: FDA Draft Guidance Recommends Info To Include In Patient-Matched Guides To Orthopedic Implants - Duane Morris LLP
Mondaq 17 Aug 2023
United States: FDA Issues New Nitrosamine Impurities Guidance - Duane Morris LLP
Mondaq 11 Aug 2023

More coverage

United States: Next Phase Of MoCRA Rollout: FDA Draft Guidance On Registration And Listing Of Cosmetic Product Facilities And Products - Duane Morris LLP

The Modernization of Cosmetics Regulation Act's (MoCRA) long-awaited rollout continues as, on August 7, 2023, FDA released draft..

Mondaq 10 Aug 2023

United States: FDA Issues Long-Awaited Draft Guidance For Industry On Registration And Listing Of Cosmetic Product Facilities And Products Under MoCRA - Duane Morris LLP

As of March 27, 2023, FDA ended its voluntary cosmetics registration program (VCRP), and advised that information submitted to VCRP..

Mondaq 08 Aug 2023

United States: Nitrosamine Impurities FDA Guidance - Duane Morris LLP

United States: Nitrosamine Impurities FDA Guidance - Duane Morris LLP

You might like

Related news coverage

United States: FDA Issues Second Warning Letter Of 2023 Over Potentially Misleading Efficacy Claims Regarding Inhaler - Duane Morris LLP

Advertisement

More coverage

United States: Next Phase Of MoCRA Rollout: FDA Draft Guidance On Registration And Listing Of Cosmetic Product Facilities And Products - Duane Morris LLP

United States: FDA Issues Long-Awaited Draft Guidance For Industry On Registration And Listing Of Cosmetic Product Facilities And Products Under MoCRA - Duane Morris LLP